Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has received approval from the National Medical ...

Four physicians spoke on the panel, which was held at the Basketball Hall of Fame in Springfield, to discuss advancements in ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as ...

Akeso (AKESF) announced that its “globally first-in-class PD-1/VEGF bispecific antibody,” ivonescimab, has received approval from the National ...

Q1 2025 Earnings Call Transcript April 24, 2025 NovoCure Limited beats earnings expectations. Reported EPS is $-0.31, ...

Guilt and shame – not hope for recovery – are among the most common reasons terminally ill cancer patients continue with minimally beneficial treatments at the end of life, according to Rutgers ...

Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.

The risk of cancer goes up with age, in part because aging impedes the body's ability to detect and destroy cells with ...

Cullinan Therapeutics (CGEM) announced that results from the REZILIENT1 study of zipalertinib in non-small cell lung cancer patients with EGFR ...

Summit Therapeutics shares rallied after its lung cancer drug candidate showed that it improved patients' longevity without the disease worsening in a late-stage trial. Shares of Summit rose 11% to ...

The regulatory approval in the EU comes approximately six months after Novocure secured FDA approval of the system.

Not only are pharmaceutical stocks excellent defensive investments, some pharma stocks pay sizable dividends that can be a ...